Literature DB >> 1513263

Definition and application of a histopathological scoring scheme for an animal model of acute Mycoplasma pneumoniae pulmonary infection.

N Cimolai1, G P Taylor, D Mah, B J Morrison.   

Abstract

A histopathological scoring system was developed to assess the pathology of acute Mycoplasma pneumoniae pulmonary infection in a hamster model. A final score per animal (ranging 0-26) is obtained by averaging scores from each lung which have been accumulated by the addition of subscores from the assessments of quantity and quality of peribronchiolar and peribronchial infiltrates, luminal exudates, perivascular infiltrates, and parenchymal pneumonia. The scoring scheme was then applied to test the ability of a heat-killed inoculum to induce pulmonary pathology and to the trial of a 43 kDa protein-associated antigen as a vaccine immunogen. A heat-killed inoculum delivered by both intratracheal and intranasal routes did not induce pulmonary pathology compared to a live inoculum (respective mean scores 0.1, 6.7; P less than 0.01). Animals prevaccinated with the 43 kDa antigen developed an accentuated pathological response after live challenge compared to those unvaccinated (respective mean scores 16.8, 5.8; P = 0.00007). Hypersensitization to growth medium components may, however, have contributed to the accentuated disease since the lungs of vaccinated animals challenged with culture-negative media also were affected (mean score 5.4). Reproducibility of the scoring system was measured by duplicate reading of histology slides which were randomized to the observer upon the second reading (r = 0.93; P = 0.000009). The scoring system has the ability to differentiate disease severity in small groups of animals.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1513263     DOI: 10.1111/j.1348-0421.1992.tb02045.x

Source DB:  PubMed          Journal:  Microbiol Immunol        ISSN: 0385-5600            Impact factor:   1.955


  59 in total

1.  SPLUNC1 promotes lung innate defense against Mycoplasma pneumoniae infection in mice.

Authors:  Fabienne Gally; Y Peter Di; Sean K Smith; Maisha N Minor; Yang Liu; Donna L Bratton; S Courtney Frasch; Nicole M Michels; Stephanie R Case; Hong Wei Chu
Journal:  Am J Pathol       Date:  2011-05       Impact factor: 4.307

2.  Fatal outcomes in family transmission of Mycoplasma pneumoniae.

Authors:  T R Kannan; R D Hardy; J J Coalson; D C Cavuoti; J D Siegel; M Cagle; O Musatovova; C Herrera; J B Baseman
Journal:  Clin Infect Dis       Date:  2011-11-03       Impact factor: 9.079

3.  Synthesis and distribution of CARDS toxin during Mycoplasma pneumoniae infection in a murine model.

Authors:  T R Kannan; Jacqueline J Coalson; Marianna Cagle; Oxana Musatovova; R Doug Hardy; Joel B Baseman
Journal:  J Infect Dis       Date:  2011-09-28       Impact factor: 5.226

4.  Variation in colonization, ADP-ribosylating and vacuolating cytotoxin, and pulmonary disease severity among mycoplasma pneumoniae strains.

Authors:  Chonnamet Techasaensiri; Claudia Tagliabue; Marianna Cagle; Pooya Iranpour; Kathy Katz; Thirumalai R Kannan; Jacqueline J Coalson; Joel B Baseman; R Doug Hardy
Journal:  Am J Respir Crit Care Med       Date:  2010-05-27       Impact factor: 21.405

5.  Antibodies to Protein but Not Glycolipid Structures Are Important for Host Defense against Mycoplasma pneumoniae.

Authors:  Patrick M Meyer Sauteur; Adrianus C J M de Bruijn; Catarina Graça; Anne P Tio-Gillen; Silvia C Estevão; Theo Hoogenboezem; Rudi W Hendriks; Christoph Berger; Bart C Jacobs; Annemarie M C van Rossum; Ruth Huizinga; Wendy W J Unger
Journal:  Infect Immun       Date:  2019-01-24       Impact factor: 3.441

6.  Phosphatidylinositol inhibits respiratory syncytial virus infection.

Authors:  Mari Numata; Pitchaimani Kandasamy; Yoji Nagashima; Rachel Fickes; Robert C Murphy; Dennis R Voelker
Journal:  J Lipid Res       Date:  2015-01-05       Impact factor: 5.922

Review 7.  Mycoplasma pneumoniae and its role as a human pathogen.

Authors:  Ken B Waites; Deborah F Talkington
Journal:  Clin Microbiol Rev       Date:  2004-10       Impact factor: 26.132

8.  Respiratory tract infection with Mycoplasma pneumoniae in interleukin-12 knockout mice results in improved bacterial clearance and reduced pulmonary inflammation.

Authors:  C M Salvatore; M Fonseca-Aten; K Katz-Gaynor; A M Gomez; A Mejias; C Somers; S Chavez-Bueno; G H McCracken; R D Hardy
Journal:  Infect Immun       Date:  2006-10-30       Impact factor: 3.441

9.  Pulmonary surfactant phosphatidylglycerol inhibits respiratory syncytial virus-induced inflammation and infection.

Authors:  Mari Numata; Hong Wei Chu; Azzeddine Dakhama; Dennis R Voelker
Journal:  Proc Natl Acad Sci U S A       Date:  2009-12-22       Impact factor: 11.205

10.  Analysis of pulmonary inflammation and function in the mouse and baboon after exposure to Mycoplasma pneumoniae CARDS toxin.

Authors:  R Doug Hardy; Jacqueline J Coalson; Jay Peters; Adriana Chaparro; Chonnamet Techasaensiri; Angelene M Cantwell; T R Kannan; Joel B Baseman; Peter H Dube
Journal:  PLoS One       Date:  2009-10-27       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.